Representatives and experts from Peking
Union Medical College Hospital, Beijing Children's Hospital, PKU China Center
for Health Development Studies, Embassy of the Republic of Korea, Coree-Ofmom
(HK) and Beijing Hanmi Group came together at Centre Ofmom in Beijing to
formalize an international research project on women’s welfare and children’s
healthcare on 3 December, 2017.
For more than one decade, Coree-Ofmom (HK)
and Beijing Hanmi Group have been working separately with some of the medical
institutes on research concerning women’s welfare and children’s healthcare.
With the rise in living standards, people are demanding more in this area.
During this meeting, participants held an in-depth discussion on the current
state of women’s welfare and children’s healthcare in China, South Korea and
across the world. Identifying special issues and common challenges, they came
to the conclusion that it was necessary for them to join forces to launch their
initiative. This joint-effort will be spearheaded by Professor Ma Liangkun of
Peking Union Medical College Hospital. Professor Ma is an expert in the field
with years of solid research, and has published his studies extensively.
Meanwhile, Catholic universities in Italy, Gemelli University Hospital in Rome
and Seoul National University will also be collaborating on the project. Result
of the research will be published to further the cause of women’s and
children’s health worldwide.
South Korean commercial attaché Joo Young
Joon, one of the participants in the meeting, said it meant a lot for the work
on women’s welfare and children’s healthcare with China’s foremost medical
institutes at the helm of the research, the result of which is expected to hit
a high standard. “This marks an important civil diplomatic achievement and the
South Korean government is fully behind it,” he said.
Born in Seoul, having spent long periods in
China and US, founder of Coree-Ofmom and CEO of Hanmi Science Lim Chong Yoon,
while being Korean, traces his ancestry back to Hakka Chinese. He said, “My
family name in Chinese is Lin, originating from Fujian Province in China 1,700
years ago. For a long time, China, Korea, Japan and many countries in Southeast
Asia existed side by side in harmony without borders. We were like a big
family; our foods were similar, and so were our lifestyles. Today, the
joint-research project by medical professionals from China and South Korea
offers a promise. It is a promise to ensure women and children in China, South
Korea and around the world will have the chance to share a peaceful, happy
future. The project is built upon a multilateral consensus. Our centers in
Rome, Beijing, Seoul and Los Angeles will be using our Symbio™ symbiosis technology
to take part in the effort. This special international project will take us
forward, in the way our forefathers did along the “Silk Road”, the “Tea Road”
and the “Milk Road”, to inaugurate a brand new “Mothers’ Road” from which
maternal love and care can be spread throughout the world.”
At last, honorary president of Beijing
Children’s Hospital Li Zhongzhi, who is also a former committee member of the
pediatrics branch of Chinese Hospital Association and standing committee member
of the Chinese Association of Pediatrics Surgeons, said the Chinese medical
sector was also opening up to the world through the “Belt And Road” initiative,
and this joint-project would be a classic example, with benefits for women and
children around the globe.
About Coree Group - Hanmi Science, founded
in 1973 in Korea, initially started as a business that focused on
pharmaceutical industry. After 40 years of development, we are now a
corporation that runs multi businesses including baby infant formula &
foods, baby consumer goods, premium prenatal & postnatal centres, music
& media and property investment. Now we have offices in Korea, Hong Kong,
Beijing, USA and Italy for strategic expansion of local markets
Hanmi Science - Hanmi Science is the
largest pharmaceutical company in Korea which subsidiary companies include
Hanmi Pharmaceuticals, Hanmi Fine Chemicals, Hanmi MediCare, Hanmi IT, Beijing
Hanmi and Hanmi online pharmaceutical (wholesaler) and JVM . Now Hanmi Science
total stock value is 6.1 trillion KRW (as of 30th Sep 2016). Its business
includes medicines, foods, mother and infant products, fine chemicals, medical
device, information technology, media and human resources.
